Stoke Therapeutics (STOK) EBT Margin (2022 - 2025)
Stoke Therapeutics (STOK) has 4 years of EBT Margin data on record, last reported at 372.71% in Q3 2025.
- For Q3 2025, EBT Margin rose 16734.0% year-over-year to 372.71%; the TTM value through Sep 2025 reached 19.63%, up 64973.0%, while the annual FY2024 figure was 242.74%, 95162.0% up from the prior year.
- EBT Margin reached 372.71% in Q3 2025 per STOK's latest filing, down from 169.95% in the prior quarter.
- Across five years, EBT Margin topped out at 71.99% in Q1 2025 and bottomed at 1237.2% in Q2 2023.
- Average EBT Margin over 4 years is 591.43%, with a median of 625.57% recorded in 2024.
- Peak YoY movement for EBT Margin: tumbled -47295bps in 2023, then skyrocketed 91631bps in 2024.
- A 4-year view of EBT Margin shows it stood at 786.32% in 2022, then dropped by -23bps to 963.56% in 2023, then skyrocketed by 95bps to 47.25% in 2024, then crashed by -689bps to 372.71% in 2025.
- Per Business Quant database, its latest 3 readings for EBT Margin were 372.71% in Q3 2025, 169.95% in Q2 2025, and 71.99% in Q1 2025.